Jeff Liter – VJRegenMed

Allogeneic therapy highlights at Advanced Therapies Week 2022

Simon Ng — Thu, 24 Mar 2022 13:14:37 +0000

Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides his highlights from Advanced Therapies Week 2022, including advances in allogeneic therapy manufacturing. He discusses developments that have led to more consistent donor material and media expansion techniques, as well as the cooperation between various companies to propel progress in the field. This interview took place at Advanced Therapies Week 2022.

Advances in allogeneic γδ T cells

Simon Ng — Tue, 22 Feb 2022 15:00:55 +0000

Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, discusses the development of allogeneic gamma delta (γδ) T cells. Whilst there has previously been a focus on autologous therapies such as LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, current attention is directed towards allogeneic therapies. The emergence of γδ T cells have been beneficial as they do not cause graft versus host disease (GvHD) and are already HLA matched between donor and patient. Dr Liter additionally highlights a proprietary Tc Buster Transposon system that enables expansion of the Vδ1 and Vδ2 subtypes of γδ T cells. This interview took place at Advanced Therapies Week 2022.

LMY-920 in non-Hodgkin lymphoma

Simon Ng — Mon, 14 Feb 2022 17:40:19 +0000

Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.

The benefits of universal immune receptors in cell therapy

Simon Ng — Mon, 14 Feb 2022 17:40:17 +0000

Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, describes the advantages of universal immune receptors and how they can address issues relating to chimeric antigen receptor (CAR) T-cell therapies. Patients receiving CAR T-cell therapies can experience antigen escape and T-cell exhaustion and universal immune receptors can overcome these issues by having the ability to be turned on or off. This property enables the antigen to be changed in the event of antigen escape and rest the T cells if T-cell exhaustion occurs. This interview took place at Advanced Therapies Week 2022.